Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

This study has been terminated.
(Study terminated due to low enrollment.)
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00244257
First received: October 25, 2005
Last updated: April 8, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2008
  Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)